Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics.

Abstract:

OBJECTIVE:Preoperative differentiation of primary and metastatic ovarian tumors is difficult. Young age of the patient, bilateralism and reduced multilocularity are cited characteristics of secondary ovarian malignancies. We sought to identity pre- and perioperative factors which may aid in differentiating metastatic ovarian tumors from primary ovarian malignancies. PATIENTS AND METHODS:We performed a retrospective analysis of demographic parameters, preoperative serum tumor marker levels and ultrasonographic as well as operative findings in 38 patients with secondary ovarian malignancies and 76 control patients with primary epithelial ovarian cancer. All patients were treated at our institute from 1996 to 2003. RESULTS:The proportion of secondary ovarian tumors, of all ovarian malignancies, was 5.2%. The most common sites of origin were the gastrointestinal tract (42%), breast (29%) and peritoneum (16%). Fifty-eight percent of the patients with a secondary ovarian tumor had a history of previous malignancy; 42% of the primary malignancies were detected only following diagnosis of ovarian metastasis. The two patient groups (primary or secondary ovarian malignancy) could not be distinguished by age, parity, menopausal status or history of hysterectomy. Of the serum markers, the preoperative level of serum CA 125 was not different between the two groups. Both serum tumor-associated trypsin inhibitor (TATI) (7.2 +/- 9.6 vs. 4.7 +/- 9.4 mug/l [mean +/- SD]) and carsinoembryonic antigen (CEA) levels (19.7 +/- 30.8 vs. 6.7 +/- 120.0 mug/l) were higher in the group with secondary malignancies (P < 0.02). The metastatic ovarian tumors, as measured preoperatively by ultrasonography (US), were smaller (64 mm, 62-89 mm [median, 95% Cl]) than the primary tumors (105 mm, 104-134 mm) (P < 0.0005). The same was true for tumor sizes measured at surgery (P < 0.05). Furthermore, the secondary tumors were more often solid (50 vs. 10%) (P < 0.005), and more seldom cystic-solid (17 vs. 55%) (P < 0.001). Presence of ascites was more common among patients with primary ovarian malignancies in both preoperative US (P < 0.01) and at operation (P < 0.0001). Bilateralism, presence of adhesions, and carcinosis did not differ between the two groups. CONCLUSIONS:When evaluating a patient with an ovarian tumor, a history of malignancy strongly suggests a metastatic nature. Size less than 9 cm, solid structure, absence of ascites and elevated serum CEA and TATI levels were typical features associated with secondary ovarian malignancies.

journal_name

Gynecol Oncol

journal_title

Gynecologic oncology

authors

Antila R,Jalkanen J,Heikinheimo O

doi

10.1016/j.ygyno.2005.09.046

subject

Has Abstract

pub_date

2006-04-01 00:00:00

pages

97-101

issue

1

eissn

0090-8258

issn

1095-6859

pii

S0090-8258(05)00844-9

journal_volume

101

pub_type

杂志文章
  • Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT).

    abstract:OBJECTIVE:To analyze the survival of women with malignant, mixed mullerian tumors of the ovary (OMMMT) compared to women with epithelial ovarian cancer (EOC). METHODS:Data from the Surveillance, Epidemiology and End Results (SEER) Program on 14025 women diagnosed with primary invasive ovarian cancer between 1988 and 1...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.02.016

    authors: Barnholtz-Sloan JS,Morris R,Malone JM Jr,Munkarah AR

    更新日期:2004-05-01 00:00:00

  • First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer.

    abstract::Current first-line management for advanced ovarian cancer consists of cytoreductive surgery followed by chemotherapy, usually with a platinum/taxane combination. Although this approach has been shown to achieve overall response rates of 70-80% in clinical trials, the majority of patients relapse. A number of different...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0090-8258(03)00472-4

    authors: Stuart GC

    更新日期:2003-09-01 00:00:00

  • Introduction of transperitoneal lymphadenectomy in a gynecologic oncology center: analysis of 650 laparoscopic pelvic and/or paraaortic transperitoneal lymphadenectomies.

    abstract:OBJECTIVE:Lymphadenectomy is an integral part of staging and treatment of gynecologic malignancies. We evaluated the feasibility and oncologic value of laparoscopic transperitoneal pelvic and paraaortic lymphadenectomy in correlation to complication rate and body mass index. METHODS:Between August 1994 and September 2...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2004.07.025

    authors: Köhler C,Klemm P,Schau A,Possover M,Krause N,Tozzi R,Schneider A

    更新日期:2004-10-01 00:00:00

  • Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.

    abstract::Mullerian Inhibiting Substance (MIS), a fetal testicular product that causes regression of the Mullerian duct in the male mammalian embryo, was evaluated for its antitumor effect on the premise that a substance active against this genital precursor in the fetus might also be active against tumors derived from these ti...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(85)90019-8

    authors: Fuller AF Jr,Krane IM,Budzik GP,Donahoe PK

    更新日期:1985-10-01 00:00:00

  • Reply

    abstract::Copyright ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5001

    authors: Posner JB

    更新日期:1998-05-01 00:00:00

  • Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.

    abstract:OBJECTIVE:The expression of homologous recombination (HR) genes in high grade ovarian cancer (HGOC) samples from debulking surgeries were correlated to outcomes in patients selected for chemotherapy treatment regimens. STUDY DESIGN:RNA was extracted from 96 fresh frozen tumor samples from debulking surgeries from chem...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2018.01.017

    authors: Kessous R,Octeau D,Klein K,Tonin PN,Greenwood CMT,Pelmus M,Laskov I,Kogan L,Salvador S,Lau S,Yasmeen A,Gotlieb WH

    更新日期:2018-03-01 00:00:00

  • A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study.

    abstract::Forty-one eligible patients with metastatic or recurrent carcinoma of the uterine cervix received 149 courses of carboplatin. The drug was administered at a starting dosage of 400 mg/m2 IV every 28 days. The overall response rate was 15% (two complete responses, four partial responses; 95% confidence interval 6-29%) a...

    journal_title:Gynecologic oncology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1016/0090-8258(90)90262-j

    authors: Weiss GR,Green S,Hannigan EV,Boutselis JG,Surwit EA,Wallace DL,Alberts DS

    更新日期:1990-12-01 00:00:00

  • Laparoscopy-assisted vaginal pelvic exenteration.

    abstract:OBJECTIVE:The aim of this study was to evaluate the feasibility, morbidity and survival outcome of laparoscopy-assisted vaginal pelvic exenteration. METHODS:Since 2000, we have performed 5 cases of en-bloc pelvic exenteration combining a vaginal or perineal approach and laparoscopic approach. All patients had received...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.09.027

    authors: Ferron G,Querleu D,Martel P,Letourneur B,Soulié M

    更新日期:2006-03-01 00:00:00

  • Epigenetics of ovarian cancer: from the lab to the clinic.

    abstract:OBJECTIVE:Ovarian cancer remains the most lethal gynaecological cancer. Various molecular changes have been identified and have shown promise for their diagnostic, prognostic and curative capacity but still need further validation. Among different mechanisms, the present article reviews the importance of epigenetic cha...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2010.03.015

    authors: Asadollahi R,Hyde CA,Zhong XY

    更新日期:2010-07-01 00:00:00

  • Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis.

    abstract::Sentinel node mapping is increasingly being utilized for endometrial cancer staging. However, only limited evidence supporting the adoption of sentinel node mapping instead of conventional lymphadenectomy is still available. Here, we aimed to review the current evidence comparing sentinel node mapping and lymphadenect...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.ygyno.2019.03.254

    authors: Bogani G,Murgia F,Ditto A,Raspagliesi F

    更新日期:2019-06-01 00:00:00

  • Strategies in late stage cervix carcinoma.

    abstract::Stage IIB-IV squamous cell carcinoma of the cervix when treated by irradiation has a significant failure rate. Causes of pelvic and distant failure are discussed. New techniques employed to improve local control and decrease distant metastasis are presented. Data on morbidity, mortality, and survival will be reviewed ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(86)90135-6

    authors: Krochak R

    更新日期:1986-03-01 00:00:00

  • Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma.

    abstract::During the period 1977 to 1985, 12 patients with FIGO stage II and III epithelial ovarian carcinoma failed to achieve a pathologic complete response with chemotherapy and underwent salvage whole-abdominal irradiation (WAXRT). Six of these patients had gross residual disease present at the time of irradiation, and thre...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90135-8

    authors: Linstadt DE,Stern JL,Quivey JM,Leibel SA,Lacey CG

    更新日期:1990-03-01 00:00:00

  • Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.

    abstract:OBJECTIVE:To examine associations between post-diagnosis use of antihypertensive (AH) medications including thiazide diuretics (TDs), angiotensin converting enzyme inhibitors (ACEIs), beta blockers (BBs) [both non-selective (NSBBs) and selective (SBBs)] and calcium channel blockers (CCBs) and ovarian cancer-specific su...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.05.030

    authors: Harding BN,Delaney JA,Urban RR,Weiss NS

    更新日期:2019-08-01 00:00:00

  • Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach.

    abstract:OBJECTIVE:The natural history of the development of ovarian carcinoma is not known. It also remains undetermined whether ovarian carcinomas develop from benign and/or borderline malignant tumors or arise de novo from the ovarian surface epithelium. METHODS:To address these issues clinicopathologically, we reviewed the...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/s0090-8258(02)00104-x

    authors: Horiuchi A,Itoh K,Shimizu M,Nakai I,Yamazaki T,Kimura K,Suzuki A,Shiozawa I,Ueda N,Konishi I

    更新日期:2003-03-01 00:00:00

  • Accuracy of preoperative cross-sectional imaging in cervical cancer patients undergoing primary radical surgery.

    abstract:OBJECTIVE:We aim to describe the false negative (FN) and false positive (FP) rates of preoperative cross-sectional imaging (PCI) prior to radical surgery for cervical cancer. METHODS:A retrospective cohort study of patients who underwent radical hysterectomy for early-stage cervical cancer from January 2010 until Dece...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.11.001

    authors: Staley SA,Tucker KR,Gehrig PA,Clark LH

    更新日期:2021-02-01 00:00:00

  • Insomnia and its association with quality of life in women with ovarian cancer.

    abstract:OBJECTIVES:Insomnia is common in women with ovarian cancer but there are limited prospective data on the frequency and degree of impact on patients. Our objective was to determine the prevalence of insomnia over the first three years after a diagnosis of ovarian cancer; and the relationship between insomnia and quality...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2020.06.500

    authors: Ross TL,DeFazio A,Friedlander M,Grant P,Nagle CM,Williams M,Webb PM,Beesley VL,OPAL Study Group.

    更新日期:2020-09-01 00:00:00

  • Detection of a small molecular species of human chorionic gonadotropin in the urine of patients with carcinoma of the cervix and cervical intraepithelial neoplasia: comparison with other assays for human chorionic gonadotropin and its fragments.

    abstract::A low-molecular-weight glycoprotein containing sequences of the beta subunit of human chorionic gonadotropin (hCG) has been found in the urine of patients with carcinoma of the cervix using an immunoradiometric assay. This fragment has chromatographic and immunological identity with hCG beta core. This molecule was pr...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(90)90343-j

    authors: Norman RJ,Buck RH,Aktar B,Mayet N,Moodley J

    更新日期:1990-05-01 00:00:00

  • Hypermethylated DAPK in serum DNA of women with uterine leiomyoma is a biomarker not restricted to cancer.

    abstract:OBJECTIVE:Ovarian cancer is most frequently diagnosed at a late stage with a poor prognosis. No markers for early diagnosis have been established. Aberrantly methylated DNA appears as a promising molecular cancer marker. The aim of this study was to analyze the methylation status of the proapoptotic cancer related gene...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.11.018

    authors: Häfner N,Diebolder H,Jansen L,Hoppe I,Dürst M,Runnebaum IB

    更新日期:2011-04-01 00:00:00

  • Management of the adnexal mass.

    abstract::The methods for preoperative diagnosis and evaluation of the woman with a suspected ovarian neoplasm have evolved significantly with little or no impact on the surgical treatment, which remains removal of the abnormal ovary. Although most adnexal masses are benign, the primary goal of the diagnostic evaluation is the ...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1006/gyno.1994.1340

    authors: Curtin JP

    更新日期:1994-12-01 00:00:00

  • Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.

    abstract:OBJECTIVE:To evaluate clinical outcomes of patients with BRCA-associated ovarian cancer who developed brain metastases (BM). METHODS:Patients with epithelial ovarian, fallopian tube, and primary peritoneal cancer (EOC) and BM, treated at a single institution from 1/1/2008-7/1/2018, were identified from two institution...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2019.05.004

    authors: Stasenko M,Cybulska P,Feit N,Makker V,Konner J,O'Cearbhaill RE,Alektiar KM,Beal K,Gardner GJ,Long Roche KC,Sonoda Y,Chi DS,Zivanovic O,Leitao MM Jr,Cadoo KA,Tew WP

    更新日期:2019-07-01 00:00:00

  • A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom.

    abstract:OBJECTIVE:To determine whether single agent chemotherapy with intramuscular methotrexate 50mg administered on days 1, 3, 5, and 7 and oral folinic acid 15mg administered on days 2, 4, 6, and 8 in 2 weekly cycles (IM MTX/FA) is an effective treatment regimen for patients with low risk gestational choriocarcinoma. METHO...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.ygyno.2014.12.024

    authors: Taylor F,Short D,Winter MC,Tidy J,Savage PM,Sarwar N,Hancock BW,Seckl MJ,Coleman RE

    更新日期:2015-02-01 00:00:00

  • The usefulness of cystoscopy in the staging of cervical cancer.

    abstract:OBJECTIVE:The aim of this study was to clarify the usefulness of cystoscopy in the staging of cervical cancer and to evaluate the clinical indications for performing ureteric catheterization to rule out ureteral obstruction in cervical cancer. METHODS:Both rigid cystoscopy and CT were performed before treatment in pat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1999.5679

    authors: Liang CC,Tseng CJ,Soong YK

    更新日期:2000-02-01 00:00:00

  • Class III NSRH: oncological outcome in 170 cervical cancer patients.

    abstract:OBJECTIVE:To analyze local recurrence rate (LRR), morbidities and oncologic outcome of class III nerve-sparing radical hysterectomy. PATIENTS AND METHODS:170 consecutive class III NSRH cases were performed. Nineteen patients were addressed directly to surgery whilst neoadjuvant chemotherapy was administered in 151 pat...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2010.07.030

    authors: Ditto A,Martinelli F,Hanozet F,Reato C,Solima E,Zanaboni F,Grijuela B,Carcangiu M,Haeusler E,Raspagliesi F

    更新日期:2010-11-01 00:00:00

  • Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.

    abstract:BACKGROUND:Ovarian sex cord stromal tumors are frequently hormonally active, and adult granulosa cell tumors often demonstrate estrogen receptor positivity. Thus, hormonal agents have been evaluated as potential treatments for advanced stage or recurrent adult granulosa cell tumors. CASE:Two cases of patients with rec...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.06.022

    authors: Freeman SA,Modesitt SC

    更新日期:2006-11-01 00:00:00

  • Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.

    abstract:BACKGROUND:Most borderline ovarian tumors (BOTs) are cured with surgery. However BOTs with invasive implants have a poor prognosis with a mortality of 20-40%. The benefit of adjuvant chemotherapy (CT) in this setting remains poorly defined. METHODS:Retrospective study of serous BOT+invasive implants treated with adjuv...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2013.11.006

    authors: Leary A,Petrella MC,Pautier P,Duvillard P,Uzan C,Tazi Y,Ledoux F,Gouy S,Morice P,Lhommé C

    更新日期:2014-01-01 00:00:00

  • PTEN expression in clear cell adenocarcinoma of the ovary.

    abstract:OBJECTIVES:In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary. Furthermore, we analyzed the expression of cyclin D1 and p27, and investigated the correlation among all these variables. METHODS:Totally, 40 clear cell adenocarcinomas were included in this stud...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2005.09.047

    authors: Hashiguchi Y,Tsuda H,Inoue T,Berkowitz RS,Mok SC

    更新日期:2006-04-01 00:00:00

  • High-risk metastatic gestational trophoblastic disease: further stratification into two clinical entities.

    abstract::Forty-two of sixty-seven patients (62.7%) treated for high-risk metastatic trophoblastic disease achieved and maintained complete remissions. The survival rate was significantly improved in those patients with scores lower than 8 according to a modification of the World Health Organization (WHO) prognostic scoring sys...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/0090-8258(89)90106-6

    authors: Gordon AN,Gershenson DM,Copeland LJ,Stringer CA,Morris M,Wharton JT

    更新日期:1989-07-01 00:00:00

  • mTOR inhibitors in breast cancer: a systematic review.

    abstract::PI3K/AKT/mTOR pathway is a crucial mediator of tumor progression. As the PI3K/Akt pathway is heavily deregulated in breast cancer, the application of mTOR inhibitors in breast cancer patients seems warranted. This is the first systematic review according to PRISMA guidelines to synthesize all available data of mTOR in...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章,评审

    doi:10.1016/j.ygyno.2012.08.040

    authors: Zagouri F,Sergentanis TN,Chrysikos D,Filipits M,Bartsch R

    更新日期:2012-12-01 00:00:00

  • Characterization of CSOC 882, a novel immortalized ovarian cancer cell line expressing EGFR, HER2, and activated AKT.

    abstract:OBJECTIVE:Only a small number of comprehensively characterized immortalized ovarian cancer cell lines are available for laboratory studies on ovarian cancer. We describe a new ovarian cancer cell line that arose from primary culture of a stage IC, grade III ovarian carcinoma, designated CSOC 882. METHODS:We characteri...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1016/j.ygyno.2006.07.023

    authors: Scoles DR,Pavelka J,Cass I,Tran H,Baldwin RL,Armstrong K,Karlan BY

    更新日期:2007-01-01 00:00:00

  • Matrix metalloproteinase 2 immunoreactive protein appears early in cervical epithelial dedifferentiation.

    abstract:OBJECTIVE:Expression of the immunoreactive protein of matrix metalloproteinase 2 (MMP-2) was studied in cervical tumors representing various stages of cell atypia and differentiation. In this study, we evaluated whether the expression of MMP-2 is an early or late event in the process of dedifferentiation and cancer pro...

    journal_title:Gynecologic oncology

    pub_type: 杂志文章

    doi:10.1006/gyno.1998.5157

    authors: Talvensaari A,Apaja-Sarkkinen M,Höyhtyä M,Westerlund A,Puistola U,Turpeenniemi T

    更新日期:1999-03-01 00:00:00